Biological therapy and the immune system in patients with chronic myeloid leukemia
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33142810" target="_blank" >RIV/61989592:15110/12:33142810 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1007/s12185-012-1116-8" target="_blank" >http://dx.doi.org/10.1007/s12185-012-1116-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s12185-012-1116-8" target="_blank" >10.1007/s12185-012-1116-8</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Biological therapy and the immune system in patients with chronic myeloid leukemia
Popis výsledku v původním jazyce
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells that has been recognized as a disease responsive to immunotherapy. Despite the huge success of the tyrosine kinase inhibitors (TKIs), CML remains for the most part incurable, probably due to treatment resistance of leukemic stem cells, which are responsible for rapid disease relapse after discontinuation of therapy. Only allogeneic stem cell transplantation enables disease eradication. In addition to the Bcr-Abl1 oncoprotein, TKIs also inhibit off-target kinases (e.g. c-kit, Src, Tec), some of them having physiological functions in immune responses. In vitro studies have implied immunomodulatory effects of TKIs and interferon-alpha (IFN-a), but comprehensive information from in vivo analyses is missing. This review summarizes the recent advances in the field of immunology of CML, including basic information about leukemia-associated antigens and peptide vaccines, that could lead to the in
Název v anglickém jazyce
Biological therapy and the immune system in patients with chronic myeloid leukemia
Popis výsledku anglicky
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells that has been recognized as a disease responsive to immunotherapy. Despite the huge success of the tyrosine kinase inhibitors (TKIs), CML remains for the most part incurable, probably due to treatment resistance of leukemic stem cells, which are responsible for rapid disease relapse after discontinuation of therapy. Only allogeneic stem cell transplantation enables disease eradication. In addition to the Bcr-Abl1 oncoprotein, TKIs also inhibit off-target kinases (e.g. c-kit, Src, Tec), some of them having physiological functions in immune responses. In vitro studies have implied immunomodulatory effects of TKIs and interferon-alpha (IFN-a), but comprehensive information from in vivo analyses is missing. This review summarizes the recent advances in the field of immunology of CML, including basic information about leukemia-associated antigens and peptide vaccines, that could lead to the in
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NT12218" target="_blank" >NT12218: Individualizovaná léčba chronických myeloproliferativních stavů a myelodysplastického syndromu - studie buněčné metabolomiky</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
International Journal of Hematology
ISSN
0925-5710
e-ISSN
—
Svazek periodika
96
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
JP - Japonsko
Počet stran výsledku
9
Strana od-do
1-9
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—